Creative Commons (CC): This is a Creative Commons license. Attribution (BY): Credit must be given to the creator. Article Views are the COUNTER-compliant sum of full text article downloads since ...

Amgen AMGN and Bristol Myers Squibb BMY are among the largest global biotechnology companies with broad and diverse portfolios. Amgen boasts one of the largest portfolios in the biotech industry ...

Amgen recently faced a legal setback, with a U.S. District Court jury finding the company liable for antitrust violations and awarding Regeneron Pharmaceuticals $406.8 million in damages.

We also discuss a new, tailored CRISPR treatment for an infant with a deadly disease, how Amgen owes Regeneron more than $400 million now, and more. From STAT’s Andrew Joseph: Lars Fruergaard ...

Federal court jury found Amgen liable for violating antitrust and tort laws by using cross-therapeutic bundled rebates to prevent Praluent ® (alirocumab) from competing in the market Jury awarded ...

The Düsseldorf Local Division of the Unified Patent Court has ruled that Amgen’s cholesterol-lowering drug Repatha does not infringe Sanofi and Regeneron's patent. The case marks the first-ever UPC ...

Today, a brief rundown of news involving Amgen and Regeneron, as well as updates from Travere Therapeutics, Allogene and Kyverna Therapeutics that you may have missed. This database now covers the 50 ...

US President Donald Trump has resurrected a plan he failed to achieve during his first term that entails setting US drug prices by benchmarking them to the prices of the same product in other ...

A Delaware federal trial jury found Thousand Oaks, California-based drug company Amgen Inc. liable Thursday for federal and state antitrust violations amounting to more than $400 million in damages.

Regeneron Pharmaceuticals won $406.8 million in damages for a lawsuit claiming Amgen violated antitrust and tort laws. A jury in a Delaware court found that Amgen violated certain laws ...

In the long-running feud between Regeneron and Amgen around the companies’ competing PCSK9 cholesterol meds, Regeneron has eked out another legal win over its rival. A federal jury in Delaware ...